Clinical Trial Update: 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors [EARLY_Phase 1]

View source ↗

Summary

Early-phase clinical trial investigating a radiolabeled anti-PD-L1 single-domain antibody (177Lu-anti-PD-L1 sdAb) in metastatic solid tumors; currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Endometrial Cancer
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Small Cell Lung Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• 177Lu-anti-PD-L1 sdAb

Snippet

Sponsor: Radiopharm Theranostics, Ltd | Conditions: PDL1 Gene Mutation, Non Small Cell Lung Cancer | EARLY_Phase 1 | Status: RECRUITING